NinePoint Medical lands $34M for high-res organ imaging

2014-03-20
Massachusetts-based NinePoint Medical Imaging closed a $34 million Series B funding round, the company announced today. NinePoint plans to use the funds to support ongoing U.S. commercial efforts for its NvisionVLE system, which provides high-res, endoscopic imaging of organs and tissues. The system can provide cross-sectional, volumetric views of organs, including tissues below the surface, the company said. The latest funding round was led by Corning Inc. (NYSE:GLW), along with founding investors Third Rock Ventures and Prospect Venture Partners. The new funds came with 3 new board members: Corning’s Curt Weinstein and independent directors Tom Miller and Mark Stautberg, according to a press release. "With new hospitals adopting the technology every month, and with the support of our investors and strategic guidance of our board, we can continue to expand our sales force to facilitate the adoption of NvisionVLE at more centers," NinePoint president & CEO Charles Carignan said in prepared remarks. "We will continue to build out our operational capacity to meet the increasing demand for our products, while also working on new features and product offerings for the future."
适应症
-
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。